NH

Nancy Hong

Board Member at San Diego Symphony

San Diego Metropolitan Area

Overview 

Nancy Hong is a Biotech Investor based in the San Diego Metropolitan Area, with a background in Biotechnology and extensive experience in the Pharmaceutical Industry. She currently serves as a Managing Director at RiverVest Venture Partners and holds board positions at multiple biotech companies, including Bluejay Therapeutics and Biolinq. Notable highlights of her career include investing in companies like Bluejay Therapeutics and Xilio Therapeutics, contributing to their successful Series C funding rounds.

Work Experience 

  • Board Member

    2021 - Current

San Diego Symphony is an American symphony orchestra company.

  • Board Member

    2021 - 2023

Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.

Raised $254,251,237.00 from Niterra Ventures, Taisho Pharmaceutical Holdings, Features Capital, Aphelion Capital, Alpha Wave Ventures, Global Health Investment Corporation, Senvest Management, AXA Investment Managers, Pegasus Tech Ventures and RiverVest.

  • Board Member

    2021 - 2023

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Raised $242,239,990.00 from Arkin Bio Ventures, RA Capital Management, T. Rowe Price, RiverVest, Frazier Life Sciences, Novo Holdings, Octagon Capital Advisors, Unicorn Capital Partners, HBM Healthcare Investments and Wellington Management.

  • Board Member

    2021 - 2023

  • Board Member

    2019 - 2023

Scout Bi is a biotechnology company that specializes in veterinary, animal health, and gene therapy.

Raised $62,290,416.00 from OrbiMed, Digitalis Ventures, Adage Capital Management, Frazier Healthcare Partners, Greenspring Associates, Correlation Ventures, RiverVest, Frazier Healthcare Partners, Companion Fund and Adage Capital Management.

  • Managing Director

    2016 - 2023

    Dr. Hong focuses on biopharmaceutical and medical device opportunities and contributes to the formation, development and business strategies of RiverVest portfolio companies. Dr. Hong joined RiverVest in 2016 and is based in San Diego with Drs. Niall O’Donnell and Pascal Krotee.

  • Board Member and Observer

    2019 - 2021

    NASDAQ: XLO

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Raised $244,300,000.00 from Bain Capital Life Sciences and Rock Springs Capital.

  • Principal at BioMed Ventures

    2015 - 2016

  • Senior Associate at BioMed Ventures

    2013 - 2015

  • Biotech Consultant

    2010 - 2013

  • Scientist

    2009 - 2009

    Novel targets and projects

Articles About Nancy

Relevant Websites